Literature DB >> 14663042

A haplotype at the PARK3 locus influences onset age for Parkinson's disease: the GenePD study.

S Karamohamed1, A L DeStefano, J B Wilk, C M Shoemaker, L I Golbe, M H Mark, A M Lazzarini, O Suchowersky, N Labelle, M Guttman, L J Currie, G F Wooten, M Stacy, M Saint-Hilaire, R G Feldman, K M Sullivan, G Xu, R Watts, J Growdon, M Lew, C Waters, P Vieregge, P P Pramstaller, C Klein, B A Racette, J S Perlmutter, A Parsian, C Singer, E Montgomery, K Baker, J F Gusella, S J Fink, R H Myers, A Herbert.   

Abstract

OBJECTIVE: To identify a haplotype influencing onset age for Parkinson's disease (PD) in the PARK3 region on chromosome 2p13.
METHODS: Single nucleotide polymorphisms (SNP) spanning 2.2 Mb and located in or near potential candidate genes were used to fine map the PARK3 region in 527 patients with familial PD, from 264 families.
RESULTS: TT homozygotes for rs1876487 (G/T) had a 7.4-year younger mean age at onset (p = 0.005) compared to patients with GT and GG genotypes. Furthermore, SNP flanking the sepiapterin reductase (7,8-dihydrobiopterin: NADP+ oxidoreductase) (SPR) gene, rs1876487 (p = 0.02) and rs1150500 (p = 0.04), were associated with younger onset age among persons who did not carry the 174 allele of D2S1394. The SPR gene is implicated in dopamine synthesis. Haplotype analysis of three SNP-rs2421095, rs1876487, rs1561244-revealed an association with onset age (p = 0.023) and a haplotype of A-T-G alleles was associated with younger onset for PD (p = 0.005).
CONCLUSIONS: A haplotype at the PARK3 locus, harboring the SPR gene, is associated with onset age of PD. This may suggest a role for the SPR gene in modifying the age at onset of PD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14663042     DOI: 10.1212/01.wnl.0000095966.99430.f4

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  10 in total

1.  Genome-wide scan linkage analysis for Parkinson's disease: the European genetic study of Parkinson's disease.

Authors:  M Martinez; A Brice; J R Vaughan; A Zimprich; M M B Breteler; G Meco; A Filla; M J Farrer; C Bétard; J Hardy; G De Michele; V Bonifati; B Oostra; T Gasser; N W Wood; A Dürr
Journal:  J Med Genet       Date:  2004-12       Impact factor: 6.318

2.  Sepiapterin reductase expression is increased in Parkinson's disease brain tissue.

Authors:  Jennifer E Tobin; Jing Cui; Jemma B Wilk; Jeanne C Latourelle; Jason M Laramie; Ann C McKee; Mark Guttman; Samer Karamohamed; Anita L DeStefano; Richard H Myers
Journal:  Brain Res       Date:  2007-01-08       Impact factor: 3.252

3.  The sepiapterin reductase gene region reveals association in the PARK3 locus: analysis of familial and sporadic Parkinson's disease in European populations.

Authors:  M Sharma; J C Mueller; A Zimprich; P Lichtner; A Hofer; P Leitner; S Maass; D Berg; A Dürr; V Bonifati; G De Michele; B Oostra; A Brice; N W Wood; B Muller-Myhsok; T Gasser
Journal:  J Med Genet       Date:  2006-01-27       Impact factor: 6.318

4.  Identification of risk and age-at-onset genes on chromosome 1p in Parkinson disease.

Authors:  Sofia A Oliveira; Yi-Ju Li; Maher A Noureddine; Stephan Zuchner; Xuejun Qin; Margaret A Pericak-Vance; Jeffery M Vance
Journal:  Am J Hum Genet       Date:  2005-06-28       Impact factor: 11.025

5.  A murine model for human sepiapterin-reductase deficiency.

Authors:  Seungkyoung Yang; Young Jae Lee; Jin-Man Kim; Sean Park; Joanna Peris; Philip Laipis; Young Shik Park; Jae Hoon Chung; S Paul Oh
Journal:  Am J Hum Genet       Date:  2006-01-31       Impact factor: 11.025

6.  Neuroprotective therapy in Parkinson's disease: current status and new directions from experimental and genetic clues.

Authors:  William Lin; Un Jung Kang
Journal:  J Clin Neurol       Date:  2005-10-20       Impact factor: 3.077

Review 7.  Genes associated with Parkinson syndrome.

Authors:  Saskia Biskup; Manfred Gerlach; Andreas Kupsch; Heinz Reichmann; Peter Riederer; Peter Vieregge; Ullrich Wüllner; Thomas Gasser
Journal:  J Neurol       Date:  2008-09       Impact factor: 4.849

Review 8.  Parkinson's Disease: Biomarkers, Treatment, and Risk Factors.

Authors:  Fatemeh N Emamzadeh; Andrei Surguchov
Journal:  Front Neurosci       Date:  2018-08-30       Impact factor: 4.677

9.  Association study of sepiapterin reductase gene promoter polymorphisms with schizophrenia in a Han Chinese population.

Authors:  Jiawu Fu; Guoda Ma; Hui Mai; Xudong Luo; Jingwen Yin; Qing Chen; Zhixiong Lin; Hua Tao; You Li; Lili Cui; Zheng Li; Juda Lin; Bin Zhao; Keshen Li
Journal:  Neuropsychiatr Dis Treat       Date:  2015-10-28       Impact factor: 2.570

Review 10.  Sepiapterin reductase: Characteristics and role in diseases.

Authors:  Yao Wu; Peng Chen; Li Sun; Shengtao Yuan; Zujue Cheng; Ligong Lu; Hongzhi Du; Meixiao Zhan
Journal:  J Cell Mol Med       Date:  2020-07-30       Impact factor: 5.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.